Cancer remains a leading cause of death globally, with the National Cancer Institute reporting nearly 20 million new cases in 2022. Craif, a startup from Nagoya University, seeks to tackle this issue with an innovative AI-powered, non-invasive urine-based test for early cancer detection. Co-founded by Ryuichi Onose after witnessing cancer's impact on his family, Craif recently completed a $22 million Series C funding round, raising its total to $57 million. This funding aims to enhance R&D and penetrate the U.S. market, expanding the reach of their novel diagnostic approach.
The test can be conducted from the comfort of a patient's home and is powered by advanced microRNA technology, facilitating early cancer detection at Stage 1.
With nearly 20 million new cancer cases in 2022, early detection is crucial, and Craif aims to revolutionize diagnostics with its non-invasive urine-based test.
Collection
[
|
...
]